Search Results - "Sandler, Alan"

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook by Garcia, Josep, Hurwitz, Herbert I., Sandler, Alan B., Miles, David, Coleman, Robert L, Deurloo, Regula, Chinot, Olivier L

“…•Bevacizumab (Avastin®), a VEGF-A targeting monoclonal antibody, was the first approved angiogenesis inhibitor.•Approved in a range of solid tumor indications,…”
Get full text

Bevacizumab in Non–Small Cell Lung Cancer by Sandler, Alan

“…Angiogenesis, the growth of new vessels from preexisting vessels, is a fundamental step in tumor growth and progression. Vascular endothelial growth factor…”
Get full text

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial by Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

“…Summary Background Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The anti-programmed death…”
Get full text

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer by Horn, Leora, Mansfield, Aaron S, Szczęsna, Aleksandra, Havel, Libor, Krzakowski, Maciej, Hochmair, Maximilian J, Huemer, Florian, Losonczy, György, Johnson, Melissa L, Nishio, Makoto, Reck, Martin, Mok, Tony, Lam, Sivuonthanh, Shames, David S, Liu, Juan, Ding, Beiying, Lopez-Chavez, Ariel, Kabbinavar, Fairooz, Lin, Wei, Sandler, Alan, Liu, Stephen V

“…In a randomized trial, the addition of atezolizumab to carboplatin and etoposide resulted in significantly longer overall survival than carboplatin and…”
Get full text

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial by Rittmeyer, Achim, MD, Barlesi, Fabrice, PhD, Waterkamp, Daniel, MD, Park, Keunchil, MD, Ciardiello, Fortunato, MD, von Pawel, Joachim, MD, Gadgeel, Shirish M, MD, Hida, Toyoaki, PhD, Kowalski, Dariusz M, PhD, Dols, Manuel Cobo, MD, Cortinovis, Diego L, PhD, Leach, Joseph, MD, Polikoff, Jonathan, MD, Barrios, Carlos, MD, Kabbinavar, Fairooz, MD, Frontera, Osvaldo Arén, MD, De Marinis, Filippo, MD, Turna, Hande, MD, Lee, Jong-Seok, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, He, Pei, PhD, Chen, Daniel S, MD, Sandler, Alan, MD, Gandara, David R, Dr

“…Summary Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and…”
Get full text

Recent progress in therapeutic antibodies for cancer immunotherapy by Lee, Anthony, Sun, Shawn, Sandler, Alan, Hoang, Tien

“…•There is a heavy focus of clinical cancer research efforts on cancer immunotherapy.•Treatment with checkpoint inhibitors has shown to improve standard of…”
Get full text

The Role of MET Receptor Tyrosine Kinase in Non‐Small Cell Lung Cancer and Clinical Development of Targeted Anti‐MET Agents by Robinson, Kyle W., Sandler, Alan B.

“…A better understanding of the pathophysiology and evolution of non‐small cell lung cancer (NSCLC) has identified a number of molecular targets and spurred…”
Get full text

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study by Dowlati, Afshin, Gray, Robert, Sandler, Alan B, Schiller, Joan H, Johnson, David H

“…Background: E4599 was a phase II/phase III trial, in which 878 patients with advanced non–small cell lung cancer were randomized to carboplatin + paclitaxel…”
Get full text

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599 by DAHLBERG, Suzanne E, SANDLER, Alan B, BRAHMER, Julie R, SCHILLER, Joan H, JOHNSON, David H

“…PURPOSE Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) with demonstrated efficacy in combination with carboplatin…”
Get full text

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599 by RAMALINGAM, Suresh S, DAHLBERG, Suzanne E, LANGER, Corey J, GRAY, Robert, BELANI, Chandra P, BRAHMER, Julie R, SANDLER, Alan B, SCHILLER, Joan H, JOHNSON, David H

“…Fit elderly patients with advanced non-small-cell lung cancer (NSCLC) benefit from platinum-based, two-drug chemotherapy. Bevacizumab (B) in combination with…”
Get full text

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial by Lopez-Chavez, Ariel, Thomas, Anish, Rajan, Arun, Raffeld, Mark, Morrow, Betsy, Kelly, Ronan, Carter, Corey Allan, Guha, Udayan, Killian, Keith, Lau, Christopher C, Abdullaev, Zied, Xi, Liqiang, Pack, Svetlana, Meltzer, Paul S, Corless, Christopher L, Sandler, Alan, Beadling, Carol, Warrick, Andrea, Liewehr, David J, Steinberg, Seth M, Berman, Arlene, Doyle, Austin, Szabo, Eva, Wang, Yisong, Giaccone, Giuseppe

“…We conducted a basket clinical trial to assess the feasibility of such a design strategy and to independently evaluate the effects of multiple targeted agents…”
Get full text

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 by Horn, Leora, Dahlberg, Suzanne E, Sandler, Alan B, Dowlati, Afshin, Moore, Dennis F, Murren, John R, Schiller, Joan H

“…To investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC)…”
Get full text

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab by SANDLER, Alan B, SCHILLER, Joan H, GRAY, Robert, DIMERY, Isaiah, BRAHMER, Julie, SAMANT, Meghna, WANG, Lisa I, JOHNSON, David H

“…Severe (grade >or= 3) pulmonary hemorrhage (PH) in advanced non-small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase…”
Get full text

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer by HERBST, Roy S, O'NEILL, Vincent J, FEHRENBACHER, Louis, BELANI, Chandra P, BONOMI, Philip D, HART, Lowell, MELNYK, Ostap, RAMIES, David, MING LIN, SANDLER, Alan

“…Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, and erlotinib, a reversible, orally available epidermal growth factor…”
Get full text

Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials by DILTS, David M, SANDIER, Alan B

“…To investigate the administrative barriers that impact the opening of clinical trials at the Vanderbilt-Ingram Cancer Center (VICC) and at VICC Affiliate…”
Get full text

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib by MILLER, Vincent A, RIELY, Gregory J, HERBST, Roy S, HELLER, Glenn, LADANYI, Marc, PAO, William, JOHNSON, David H, ZAKOWSKI, Maureen F, LI, Allan R, PATEL, Jyoti D, HEELAN, Robert T, KRIS, Mark G, SANDIER, Alan B, CARBONE, David P, TSAO, Anne

“…We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype,…”
Get full text

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas by Gore, Lia, Rothenberg, Mace L., O'Bryant, Cindy L., Schultz, Mary Kay, Sandler, Alan B., Coffin, Denise, McCoy, Candice, Schott, Astrid, Scholz, Catherine, Eckhardt, S. Gail

“…Purpose: To evaluate the toxicity profile, pharmacologic, and biological properties of 3-pyridylmethyl N -{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate…”
Get full text

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer by Herbst, Roy S, Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E, Sandler, Alan, Kris, Mark G, Tran, Hai T, Klein, Pam, Li, Xin, Ramies, David, Johnson, David H, Miller, Vincent A

“…Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with…”
Get full text

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study by Horn, Leora, Gettinger, Scott N., Gordon, Michael S., Herbst, Roy S., Gandhi, Leena, Felip, Enriqueta, Sequist, Lecia V., Spigel, David R., Antonia, Scott J., Balmanoukian, Ani, Cassier, Philippe A., Liu, Bo, Kowanetz, Marcin, O'Hear, Carol, Fassò, Marcella, Grossman, William, Sandler, Alan, Soria, Jean-Charles

“…Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we…”
Get full text

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer by HEYMACH, John V, PAZ-ARES, Luis, BONOMI, Philip D, HERBST, Roy S, KREBS, Annetta D, VASSELLI, James, JOHNSON, Bruce E, DE BRAUD, Filippo, SEBASTIAN, Martin, STEWART, David J, EBERHARDT, Wilfried E. E, RANADE, Anantbhushan A, COHEN, Graham, TRIGO, Jose Manuel, SANDIER, Alan B

“…Vandetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The antitumor…”
Get full text